Solu-Medrol Indications/Uses



Full Prescribing Info
When oral therapy is not feasible and the strength, dosage form and route of administration reasonably lend Solu-Medrol to the treatment of the condition, it is indicated for IV or IM use in the following conditions:
Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia, hypercalcemia associated with cancer and nonsuppurative thyroiditis.
Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis; synovitis of osteoarthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); acute and subacute bursitis; epicondylitis; acute nonspecific tenosynovitis; acute gouty arthritis; psoriatic arthritis; and ankylosing spondylitis.
Collagen Diseases (Immune Complex Diseases): During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus (and lupus nephritis); systemic dermatomyositis (polymyositis); and acute rheumatic carditis.
Dermatologic Diseases: Pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, bullous dermatitis herpetiformis, severe seborrheic dermatitis, severe psoriasis and mycosis fungoides.
Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma, contact dermatitis, atopic dermatitis, serum sickness, seasonal or perennial allergic rhinitis, drug hypersensitivity reactions, urticarial transfusion reactions and acute non-infectious laryngeal edema (epinephrine is the drug of choice).
Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye eg, herpes zoster ophthalmicus; iritis, iridocyclitis; chorioretinitis; diffuse posterior uveitis and choroiditis; keratitis; sympathetic ophthalmia; allergic conjunctivitis; allergic corneal marginal ulcers and optic neuritis.
Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) and regional enteritis (systemic therapy).
Respiratory Diseases: Symptomatic sarcoidosis, berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; Loeffler's syndrome not manageable by other means; and aspiration pneumonitis.
Hematologic Disorders: Acquired (autoimmune) hemolytic anemia; idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated), erythroblastopenia (RBC anemia); secondary thrombocytopenia in adults; and congenital (erythroid) hypoplastic anemia.
Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults and acute leukemia of childhood.
Terminal Cancer: To improve the quality of life in patients with terminal cancer.
Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
Nervous System: Cerebral Edema from Tumor: Primary or metastatic and/or associated with surgical or radiation therapy.
Acute exacerbations of multiple sclerosis. Acute spinal cord injury. The treatment should begin within 8 hrs of injury.
Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in